Aditya SinghChetna Modi , Bhupendra Gopalbhai Prajapati , Sudarshan Singh , Shubhrat Maheshwari2024-10-242024978-0-443-13205-6https://doi.org/10.1016/B978-0-443-13205-6.00028-5http://136.232.12.194:4000/handle/123456789/913Book: Alzheimer's Disease and Advanced Drug Delivery Strategies Edited by: Bhupendra Gopalbhai Prajapati, Dinesh Kumar Chellappan and Prakash N. KendreAlzheimer's disease (AD) is a progressive neurological disorder that affects the brain and leads to decline in cognitive function, memory, thinking, behavior. Alzheimer's disease is the most common cause of dementia, accounting for 60%–80% of all cases. The exact cause of AD is still not fully, however it is thought to involve a combination of genetic, environmental, and lifestyle factors. There is currently no exact medication and drug delivery available that can cure for AD, but there are several treatments available that can help in managing symptoms and slow the progression of the disease. These treatments include medication, behavioral interventions, and lifestyle changes, such as exercise and a healthy diet. Additionally, ongoing research is focused on developing nanotechnology-based new therapies and approaches such as nanoparticles, solid lipid nanoparticles, vesicular drug delivery, and dendrimers to prevent, slow, or cure AD. with Dendrimers in AD act as carrier for drug that target the β-amyloid plaques and T-tangles that are characteristic of the characteristic of the disease. Dendrimers can conjugate with drugs, enabling them to be delivered to the brain and penetrate the blood-brain barrier. Moreover, dendrimers have been reported as imaging agent that help in detection and monitoring the progression of AD. In this chapter a brief overview on dendrimers synthesis, characterization, and conjugation with drugs for treatment and management AD elaborated.en-USAlzheimer’s diseasedrug deliveryPHARMACYBook chapter